Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Pyrotinib Combined With Thalidomide in Advanced Non-Small-Cell Lung Cancer With HER2 Exon 20 Insertions: A Prospective, Single-arm, Open-label Phase II Study

Next Previous
Trial Profile

Safety and Efficacy of Pyrotinib Combined With Thalidomide in Advanced Non-Small-Cell Lung Cancer With HER2 Exon 20 Insertions: A Prospective, Single-arm, Open-label Phase II Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pyrotinib (Primary) ; Thalidomide (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms PRIDE

Most Recent Events

  • 16 Sep 2021 According to trial design published in the BMC Cancer, enrolment is estimated to be completed in Dec 2021 for the first stage and in Dec 2022 for the second stage.
  • 16 Sep 2021 Trial design published in the BMC Cancer
  • 26 Jan 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top